Cart is empty Early improvements in cardiac and hematologic parameters may predict better survival outcomes for patients being treated for stage IIIb AL amyloidosis, a deadly disease with a median survival of four to six months caused by abnormal protein buildup, according to research published in Blood Advances.
Leave A Comment